Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

October 1, 2026

Conditions

Diabetic Kidney DiseaseType 1 Diabetes

Interventions

DRUG

dapagliflozin

dapagliflozin 5 MG/10 MG once daily

DRUG

ACE inhibitor

Trial Locations (1)

Nanjing Medical University First Affiliated Hospital, Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06532682 - Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes | Biotech Hunter | Biotech Hunter